Key facts
- 35Pharma’s last known valuation is $950.0M (Apr 2026).
- It has raised $70.0M; the latest was Merger/Acquisition ($950.0M) in Apr 2026.
- Notable investors include Logos Capital, Frazier Healthcare Partners, Marshall Wace, Vivo Capital, Surveyor Capital — 10 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for 35Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for 35Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 35Pharma
Operator of a biopharmaceutical company intended for pulmonary hypertension and musculoskeletal disorders. The company combines protein engineering expertise with a deep understanding of transforming growth factor-beta structure-function relationships to design potent ligand traps for cardiovascular and metabolic diseases, enabling scientists to develop biologics for treating patients.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2021
- Employees
- 45
- Website
- 35pharma.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
35Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 35Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 35Pharma in its N-PORT filings yet. We sweep new filings monthly.